Mylan Inc. reports that the US District Court for the District of New Jersey granted its motion for a permanent injunction against GlaxoSmithKline (GSK) in relation to Paroxetine CR, the generic version of GSK’s antidepressant Paxil CR. GSK is now precluded from supplying product to Apotex, which marketed the product as an authorized generic. Mylan had previously been awarded damages in the amount of $106.7 million by the District Court after a favorable jury verdict in March 2014. 

​In addition, the District Court awarded Mylan prejudgment interest and permitted it to take an accounting so that Mylan can determine the amount of additional damages it has suffered since September 30, 2013 as a result of GSK’s ongoing breach, according to Mylan. All of GSK’s post-trial motions were denied, noted Mylan in a statement.

Mylan’s claims were based on 2007 agreements with GSK relating to Mylan’s abbreviated new drug application for paroxetine hydrochloride extended-release (ER) tablets. Pursuant to those agreements, Mylan obtained certain intellectual property rights from GSK and launched its generic paroxetine hydrochloride ER tablets in May 2008.  

Source: Mylan